ResourceLife Sciences
Ultrasensitive assays for alpha synuclein biomarkers in neurodegeneration research
12 May 2026This resource highlights ultrasensitive assays for measuring total α‑synuclein and phosphorylated α‑synuclein (pS129) as key biomarkers in Parkinson’s disease and related synucleinopathies. Using the SPEAR UltraDetect™ α‑syn and pS129‑α‑syn assays, researchers can achieve femtogram‑level detection in plasma, serum, and cerebrospinal fluid, enabling precise quantification and longitudinal monitoring of disease‑associated changes. The assays support improved biomarker discovery and therapeutic research by enabling sensitive detection of low‑abundance targets and analysis of biomarker ratios for disease differentiation.
Links
Tags
BiomarkersBiomarkers are biological markers which can be measured and evaluated to indicate a biological state. The use of biomarkers in research and diagnosis can indicate a normal or disease state or drug response of cells / tissues. Biomarkers include genetic markers, cell surface markers such as antigens, antibodies or receptors and secreted molecules such as cytokines. An assay system is required for identification of biomarkers. :Parkinsons DiseaseNeurodegenerationNeurodegeneration refers to the progressive deterioration of the structure and function of the nervous system, often seen in diseases like Alzheimer's and Parkinson's. Research focuses on early detection and potential therapies. Explore neurodegeneration research tools in our peer-reviewed product directory; compare products, check reviews, and get pricing directly from manufacturers.Biomarker DiscoveryClinical biomarkers refer to substances related to known medical conditions that can be accurately measured <i>in vitro</i>. Biomarkers can be used to diagnose presence of a disease and indicate disease severity. The discovery of new biomarkers is incredibly valuable in the field of diagnostics.Translational Research